Profound Medical Set to Release Third Quarter Financial Results
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a leading medical device company specializing in innovative, incision-free therapies for treating disease, is gearing up to deliver its financial results for the third quarter of 2024. Investors and stakeholders will be eagerly awaiting the insights that come with these results, expected to be released following the market's close.
Conference Call Details
The management team at Profound will hold a conference call at 4:30 p.m. ET to discuss the financial performance from the last quarter and share updates on the company's strategic direction.
Why Attend the Conference Call?
This event will not only cover the latest financial data but also shed light on ongoing and upcoming projects that could shape the company's future. Stakeholders will have an opportunity to engage with Profound’s leadership and gain valuable insights into their innovative approaches and market strategies.
About Profound Medical Corp.
As a commercial-stage medical device company, Profound is committed to bringing advanced therapies to patients without the need for surgeries. The flagship product, TULSA-PRO®, represents a significant breakthrough in prostate disease treatment. This technology combines real-time MRI imaging and robotically-controlled ultrasound for precise tissue ablation. TULSA-PRO® allows for minimal disruption while effectively treating conditions such as prostate cancer and benign prostatic hyperplasia (BPH).
The TULSA procedure is noteworthy for its unique approach. It delivers heat to the targeted tissue without requiring incisions or extensive recovery periods. This is particularly beneficial for patients who may be anxious about traditional surgical options. As a result, TULSA-PRO® is carving a niche as a go-to treatment method that meets the needs of varying patient profiles and conditions.
Innovative Therapeutics on the Horizon
In addition to TULSA-PRO®, Profound is also advancing Sonalleve®, an exceptional technology designed for treating uterine fibroids and alleviating pain from bone metastases. Recently sanctioned in multiple jurisdictions, Sonalleve® represents a growing sector within the company's portfolio as they explore further applications of the technology.
With its existing approvals and clinical evidence supporting its efficacy, Sonalleve® is also setting its sights on additional markets where non-invasive ablation techniques could revolutionize treatment options for various forms of cancer.
Looking Ahead: Profound’s Growth Strategy
As Profound Medical Corp. prepares for its pivotal financial call, there is significant intrigue about the upcoming developments and how they align within the company's overarching growth strategy. The focus remains on establishing a stronger presence in the non-invasive treatment market and expanding their portfolio of innovative medical technologies.
By continuously enhancing their product offerings, Profound is well-positioned to take advantage of a growing demand for less invasive treatment methods, catering to a diverse patient population.
Contact Information
For more information about Profound Medical's upcoming conference call and developments, please reach out to:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Frequently Asked Questions
What is the main focus of Profound Medical Corp.?
Profound Medical Corp. specializes in developing incision-free therapies for ablation of diseased tissue, particularly for prostate-related conditions.
When will Profound Medical announce its financial results?
The financial results for the third quarter of 2024 will be released after market close on November 7, 2024.
What are the key products offered by Profound Medical?
The key products include TULSA-PRO® for prostate treatments and Sonalleve® for uterine fibroid treatments and pain management.
How can investors participate in the conference call?
Investors can join the conference call by registering through the provided link and participating in the discussion.
What approvals does TULSA-PRO® have?
TULSA-PRO® is CE marked, approved by Health Canada, and has received 510(k) clearance from the U.S. FDA.